Browse treatments

…iated or higher-risk innovation.This tension is not confined to immunotherapy. The antibody drug conjugate (ADC) field provides a forward-loo…

…are diseases, allowing for timely initiation of the appropriate immunotherapy that ultimately led to rapid and significant clinical improveme…

…estive (24%), and breast (12%) cancer. Treatments received were chemotherapy (70.2%), immunotherapy (22.2%), and targeted therapies (11.4%);…

…nts receiving chemotherapy, immunotherapy, targeted therapy, or hormone therapy. The same 31-item questionnaire used in a 2017 baseline study w…

…t affected age group was 60–79 years (62%). Main therapies were chemotherapy (38%), immunotherapy (31%), biological therapy (21%), and other…

…rch in population and basic studies. The research hotspots were minimally invasive treatments for valve disease, circulatory haemodynamics, and prevention an…

…ite limited evidence regarding the treatment of metastatic MCC, anti-programmed cell death protein 1 immunotherapy has emerged as a primary strategy for managing advanced stages …

… L, Zhang N, Li D, et al Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macroph…

…ing tumour DNA (ctDNA) measurements to evaluate the efficacy of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC). T…

…all cell lung cancer (NSCLC) exhibit heterogeneous responses to immunotherapy (IT) with high resistance rates, highlighting the need for prec…

…nexplained encephalitis and NORSE, and support the early use of immunotherapy when an immune-mediated pathology is suspected.…

…ity to evade the immune system. Nevertheless, immunotherapy and oncolytic virotherapy are emerging as promising strategies. This study aimed to evalu…